Skip Navigation


NDT Advance Access originally published online on December 29, 2005
Nephrology Dialysis Transplantation 2006 21(3):573-576; doi:10.1093/ndt/gfk014
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
21/3/573    most recent
gfk014v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Redon, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Redon, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Editorial Comment

Measurement of microalbuminuria – what the nephrologist should know

Josep Redon

Hypertension Clinic, Department of Internal Medicine, Hospital Clínico, University of Valencia, Valencia, Spain

Correspondence and offprint requests to: Josep Redon, Hypertension Clinic, Internal Medicine, Hospìtal Clinico, Avda Blasco Ibañez, 17 46010 Valencia, Spain. Email: josep.redon@uv.es

Keywords: microalbuminuria; urinary albumin excretion; hypertension; diabetes; cardiovascular risk

The first 150 words of the full text of this article appear below.



   Introduction
 
During the last few years, a subtle increase in urinary albumin excretion (UAE) not detectable by routine methods, so called microalbuminuria, has been identified as a prognostic marker for renal and/or cardiovascular risk in diabetic and non-diabetic subjects [1]. Consequently, assessment of microalbuminuria is now recommended as a risk stratification strategy not only in diabetic subjects, but also in the management of hypertensive patients [2–5]. In order to make the best clinical use of UAE, the physician who measures UAE should know several facts:

  1. what kind of albumin molecules are present in the urine, and which methods are most suitable for assessing each of them;
  2. what method of urine sampling is recommended and how should one interpret the UAE values;
  3. how can one reduce the variability of the UAE estimate and
  4. how should one evaluate the results and manage the patient based on the results of . . . [Full Text of this Article]



   Methods to measure urinary albumin
 


   Methods to report UAE
 


   Variability of UAE
 


   Evaluation of UAE
 


   Conclusions
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Chem.Home page
M. J. McQueen and A. C. Don-Wauchope
Requesting and Interpreting Urine Albumin Measurements in the Primary Health Care Setting
Clin. Chem., October 1, 2008; 54(10): 1595 - 1597.
[Full Text] [PDF]